Skip to Content
Merck
All Photos(1)

Documents

PLA0302

Sigma-Aldrich

Goat anti-GAPDH Antibody, Affinity Purified

Powered by Bethyl Laboratories, Inc.

Synonym(s):

G3PD, GAPD, GAPDH, HEL-S-162eP, aging-associated gene 9 protein, epididymis secretory sperm binding protein Li 162eP, peptidyl-cysteine S-nitrosylase GAPDH

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

goat

Quality Level

100

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

grade

Powered by Bethyl Laboratories, Inc.

species reactivity

human, mouse

concentration

1 mg/mL

technique(s)

immunohistochemistry: 1:500-1:2,000
western blot: 1:500- 1:2,500

accession no.

NP_002037.2

UniProt accession no.

P04406

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

goat ... GAPDH(2597)

Immunogen

The epitope recognized by PLA0302 maps to a region between residue 175 and 225 of human Glyceraldehyde-3-Phosphate Dehydrogenase using the numbering given in entry NP_002037.2 (GeneID 2597).

Physical form

Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide

Other Notes

In the process of carbohydrate metabolism, GAPDH (glyceraldehydes-3-phosphate dehydrogenase) catalyzes the oxidative phosphorylation of glyceraldehydes-3-phosphate to 1,3-diphosphoglycerate in the presence of nicotinamide adenine dinucleotide (NAD) and inorganic phosphate. In addition to its role in the oxidation of glucose, GAPDH has been shown to be involved in other cellular processes such as vesicle transport, DNA repair, DNA replication, cytoskeletal modulation, and tRNA export.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xiaolei Lian et al.
Acta neuropathologica communications, 9(1), 88-88 (2021-05-19)
Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients each year in the United States. DIPG is noted for its lethality, as fewer than 1% of patients survive to five years. Multiple clinical trials
Lesya V Zelenchuk et al.
PloS one, 9(5), e97326-e97326 (2014-05-21)
PHEX or DMP1 mutations cause hypophosphatemic-rickets and altered energy metabolism. PHEX binds to DMP1-ASARM-motif to form a complex with α5β3 integrin that suppresses FGF23 expression. ASARM-peptides increase FGF23 by disrupting the PHEX-DMP1-Integrin complex. We used a 4.2 kDa peptide (SPR4)
Amane Araki et al.
Neurology, 82(20), 1813-1821 (2014-04-25)
The aim of this study was to clarify myocardial involvement and its clinical implications in subjects with spinal and bulbar muscular atrophy (SBMA), a neuromuscular disease affecting both neuronal and nonneuronal tissues. Two independent cardiologists evaluated ECGs from a total
Bo Cao et al.
Oncotarget, 5(6), 1646-1656 (2014-04-12)
Upregulation of constitutively-active androgen receptor splice variants (AR-Vs) has been implicated in AR-driven tumor progression in castration-resistant prostate cancer. To date, functional studies of AR-Vs have been focused mainly on their ability to regulate gene expression independent of the full-length
Paul Cottu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4314-4325 (2014-06-21)
Patients with luminal breast cancer (LBC) often become endocrine resistant over time. We investigated the molecular changes associated with acquired hormonoresistances in patient-derived xenografts of LBC. Two LBC xenografts (HBCx22 and HBCx34) were treated with different endocrine treatments (ET) to
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service